Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4462665 | 0.91 | BRAF (0.69) | BRAF | |
| SCHEMBL1798710 | 0.85 | BRAF (0.78) | BRAFTSHR | |
| SCHEMBL1793265 | 0.84 | BRAF (0.78) | BRAF | |
| SCHEMBL1794903 | 0.82 | BRAF (0.86) | BRAF | |
| SCHEMBL1794898 | 0.82 | BRAF (0.78) | BRAF | |
| SCHEMBL1794691 | 0.81 | BRAF (0.84) | BRAF | |
| SCHEMBL4460261 | 0.77 | BRAF (0.73) | BRAF | |
| SCHEMBL13566555 | 0.77 | BRAF (0.74) | BRAF | |
| SCHEMBL12652444 | 0.77 | BRAF (0.56) | BRAF | |
| SCHEMBL4460231 | 0.76 | BRAF (0.71) | BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2013207-B1 | IMIDAZO[4,5-B]PYRIDIN-2-ONE COMPOUNDS AND ANALOGS THEREOF AS CANCER THERAPEUTIC COMPOUNDS | CANCER REC TECH LTD (GB) | 2012-04-25 | — | — | EP | disclosed |
| EP-2013207-B1 | IMIDAZO[4,5-B]PYRIDIN-2-ONE COMPOUNDS AND ANALOGS THEREOF AS CANCER THERAPEUTIC COMPOUNDS | CANCER REC TECH LTD (GB) | 2012-04-25 | — | — | EP | disclosed |
| US-7951819-B2 | Imidazo[4, 5-B]pyridin-2-one and oxazolo[4, 5-B] pyridin-2-one compounds and analogs thereof as cancer therapeutic compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-05-31 | — | — | US | disclosed |
| US-7951819-B2 | Imidazo[4, 5-B]pyridin-2-one and oxazolo[4, 5-B] pyridin-2-one compounds and analogs thereof as cancer therapeutic compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-05-31 | — | — | US | disclosed |
| US-7951819-B2 | Imidazo[4, 5-B]pyridin-2-one and oxazolo[4, 5-B] pyridin-2-one compounds and analogs thereof as cancer therapeutic compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-05-31 | — | — | US | disclosed |
| US-20090325945-A1 | IMIDAZO[4, 5-B]PYRIDIN-2-ONE AND OXAZOLO[4, 5-B]PYRIDIN-2-ONE COMPOUNDS AND ANALOGS THEREOF AS CANCER THERAPEUTIC COMPOUNDS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2009-12-31 | — | — | US | disclosed |
| US-20090325945-A1 | IMIDAZO[4, 5-B]PYRIDIN-2-ONE AND OXAZOLO[4, 5-B]PYRIDIN-2-ONE COMPOUNDS AND ANALOGS THEREOF AS CANCER THERAPEUTIC COMPOUNDS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2009-12-31 | — | — | US | disclosed |
| US-20090325945-A1 | IMIDAZO[4, 5-B]PYRIDIN-2-ONE AND OXAZOLO[4, 5-B]PYRIDIN-2-ONE COMPOUNDS AND ANALOGS THEREOF AS CANCER THERAPEUTIC COMPOUNDS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2009-12-31 | — | — | US | disclosed |
| EP-2013207-A1 | IMIDAZO[4, 5-B]PYRIDIN-2-ONE AND OXAZOLO[4, 5-B]PYRIDIN-2-ONE COMPOUNDS AND ANALOGS THEREOF AS CANCER THERAPEUTIC COMPOUNDS | Cancer Research Technology Limited (GB) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007125330-A1 | IMIDAZO[4, 5-B]PYRIDIN-2-ONE AND OXAZOLO[4, 5-B]PYRIDIN-2-ONE COMPOUNDS AND ANALOGS THEREOF AS CANCER THERAPEUTIC COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007125330-A1 | IMIDAZO[4, 5-B]PYRIDIN-2-ONE AND OXAZOLO[4, 5-B]PYRIDIN-2-ONE COMPOUNDS AND ANALOGS THEREOF AS CANCER THERAPEUTIC COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325945-A1 | IMIDAZO[4, 5-B]PYRIDIN-2-ONE AND OXAZOLO[4, 5-B]PYRIDIN-2-ONE COMPOUNDS AND ANALOGS THEREOF AS CANCER THERAPEUTIC COMPOUNDS | NR2E1, NR0B1, NR2E3 | BRAF 5/4885TSHR 1005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.